Skip to main content

Table 1 Patient characteristics and clinicopathological variables of the study cohorts

From: Molecular analyses of triple-negative breast cancer in the young and elderly

  All patients Patients < 40 years Patients 40–50 years Patients 50–60 years Patients 60–70 years Patients 70–80 years Patients ≥ 80 years Statistical difference between age groupsE
N 237 28 24 55 53 40 37  
ER IHC % (1–10%) A 12.3% 10.7% 16.7% 9.3% 15.1% 10.3% 13.5% p = 1.0
Tumor size > 20 mm 49.4% 46.4% 37.5% 40.0% 50.9% 42.5% 78.4% p = 0.09
Grade 3 (%) 87.9% 96.3% 100% 94.3% 78.4% 80% 86.5% p = 0.29
Median Ki67% 70 87 78 70 70 58 60  
Node positive (%) 34.6% 37.0% 29.2% 32.1% 34.0% 37.5% 37.8% p = 1.0
Adjuvant chemotherapy (%) 72.8% 100% 100% 94.5% 84.9% 59.0% 0% p = 4e−15
Outcome
 Death events (%) 26.6% 17.9% 0% 12.7% 32.1% 27.5% 62.2% p = 3e−6
 IDFS events (%) 32.5% 25.0% 12.5% 16.4% 39.6% 35.0% 62.2% p = 0.0007
 Distant metastases (%) 20.7% 21.4% 8.3% 14.5% 28.3% 20.0% 27.0% p = 1.0
BRCA1-germline (%) B 8.0% 28.6% 4.2% 12.7% 1.9% 5.0% 0% p = 0.003
BRCA1 status
BRCA1-null C (%) 10.5% 32.1% 4.2% 16.4% 7.5% 5.0% 0% p = 0.006
BRCA1 hypermethylation (%) 24.1% 50.0% 41.7% 21.8% 28.3% 10.0% 5.4% p = 0.001
BRCA1 wildtype D 65.4% 17.9% 54.1% 61.8% 64.2% 85% 94.6% p = 2e−8
HRD status         p = 1e−6
 HRDetect-high (%) 58.6% 92.9% 83.3′% 67.3% 60.4% 27.5% 35.1%
 HRDetect-intermediate (%) 5.5% 0% 4.2% 5.5% 1.9% 5.0% 16.2%
 HRDetect-low (%) 35.9% 7.1% 12.5% 27.3% 37.7% 67.5% 48.6%
 PD-L1 positivity (%) 51.8% 65.4% 54.5% 62.7% 46.0% 40.0% 44.1% p = 1.0
TILs (%)         p = 1.0
 < 30% 61.5% 46.2% 40.9% 51.0% 73.5% 76.5% 69.7%
 30–50% 17.8% 19.2% 31.8% 24.5% 10.2% 11.8% 15.2%
 > 50% 20.7% 34.6% 27.3% 24.5% 16.3% 11.8% 15.2%
PAM50 subtypes (%)         p = 0.001
 Basal-like 79.9% 100% 95.7% 94.3% 73.5% 57.1% 63.9%
 HER2-enriched 14.7% 0% 4.3% 1.9% 16.3% 28.6% 36.1%
 Luminal A 1.3% 0% 0% 0% 2.0% 5.7% 0%
 Luminal B 0.4% 0% 0% 0% 0% 2.9% 0%
 Normal-like 3.6% 0% 0% 3.8% 8.2% 5.7% 0%
TNBC subtypes (%)         p = 0.22
 BL1 20.2% 14.3% 26.1% 26.4% 20.4% 14.7% 16.7%
 BL2 9.9% 10.7% 8.7% 11.3% 10.2% 5.9% 11.1%
 IM 20.2% 25.0% 21.7% 28.3% 14.3% 17.6% 13.9%
 LAR 13.0% 0% 0% 3.8% 16.3% 23.5% 30.6%
 M 18.4% 17.9% 21.7% 18.9% 20.4% 8.8% 22.2%
 MSL 6.3% 7.1% 13.0% 1.9% 4.1% 17.6% 0%
 UNS 12.1% 25.0% 8.7% 9.4% 14.3% 11.8% 5.6%
IntClust10 subtypes         p = 0.07
 1 0.9% 0% 4.3% 0% 0% 0% 2.8%
 10 64.7% 89.3% 87.0% 79.2% 57.1% 40.0% 44.4%
 3 2.2% 0% 4.3% 1.9% 2.0% 5.7% 0%
 4 25.0% 3.6% 4.3% 17.0% 30.6% 40.0% 44.4%
 5 0.9% 0% 0% 0% 2.0% 2.9% 0%
 8 0.4% 0% 0% 0% 0% 2.9% 0%
 9 5.8% 7.1.% 0% 1.9% 8.2% 8.6% 8.3%
  1. Proportions calculated excluding missing data. Groups are defined as, e.g., ≥ 40 and < 50
  2. AProportion of cases with an ER IHC staining of 1–10%, which is classified as ER-negative in Sweden
  3. BGermline alteration according to WGS analysis
  4. CBRCA1-null: germline and/or biallelic inactivation of BRCA1 determined by WGS
  5. DPatients that are not defined as BRCA1-null or show somatic BRCA1 promoter hypermethylation based on available data for the study
  6. EChi-square test, with multiple testing correction by Bonferroni adjustment (n = 18 tests)